Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML
المؤلفون المشاركون
Shinozaki-Ushiku, Aya
Kurokawa, Mineo
Kage, Hidenori
Watanabe, Kousuke
Nagoshi, Saki
Toyama, Kazuhiro
Ohno, Yoshiyuki
Nakazaki, Kumi
Suzuki, Hiroshi
Nagase, Takahide
المصدر
Case Reports in Oncological Medicine
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-03-19
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Tyrosine kinase inhibitor (TKI) combination is expected to increase in the era of precision medicine.
TKI combination may be required to treat double primary cancers, each having a targetable gene, or to treat a single malignancy with multiple targetable genes.
Here, we demonstrate the first report of dual EGFR and ABL TKI treatment in a patient with concomitant EGFR-mutated lung adenocarcinoma and BCR-ABL1-positive chronic myeloid leukemia (CML).
A 60-year-old man with an 8-year history of CML was diagnosed as advanced EGFR-mutated lung adenocarcinoma.
Complete molecular response of CML had been achieved by imatinib, and ABL-TKI had been switched to nilotinib four years previously due to muscle cramps.
We discontinued nilotinib and started afatinib.
Although partial response of lung adenocarcinoma was achieved, cytogenetic relapse of CML was observed following nilotinib discontinuation.
We applied the previously described framework of cytochrome P450 3A4-mediated oral drug-drug interactions and selected gefitinib and nilotinib to treat both malignancies.
We effectively and safely administered this combination for seven months.
The present report is the first to demonstrate the safety and efficacy of dual EGFR and ABL TKI treatment in a patient with concomitant EGFR-mutated lung adenocarcinoma and CML.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Watanabe, Kousuke& Kage, Hidenori& Nagoshi, Saki& Toyama, Kazuhiro& Ohno, Yoshiyuki& Shinozaki-Ushiku, Aya…[et al.]. 2020. Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML. Case Reports in Oncological Medicine،Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1149400
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Watanabe, Kousuke…[et al.]. Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML. Case Reports in Oncological Medicine No. 2020 (2020), pp.1-6.
https://search.emarefa.net/detail/BIM-1149400
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Watanabe, Kousuke& Kage, Hidenori& Nagoshi, Saki& Toyama, Kazuhiro& Ohno, Yoshiyuki& Shinozaki-Ushiku, Aya…[et al.]. Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML. Case Reports in Oncological Medicine. 2020. Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1149400
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1149400
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر